



100% bio-based L-methionine programme

METabolic EXplorer announces the signature of a memorandum of understanding with Technip

Clermont-Ferrand, 15 April 2015 – METabolic EXplorer, a biological chemistry company that specialises in developing manufacturing bioprocesses for the bio-based compounds used in a wide range of everyday products, including textile fibres, animal feed and resins, is today announcing the start-up of the initial phase in its 2015-2017 roadmap on the industrial development of its 100% bio-based L-methionine technology.

METabolic EXplorer is today announcing the signature of a memorandum of understanding with Technip France aimed at initiating a collaborative effort focused on the first industrial production solution for completely bio-based L-methionine.

After an initial collaborative phase aimed at the optimisation of the investment involving variable unit sizes, today's MOU with Technip is also part of a shared ambition to develop a commercial offering including engineering support for future licence-holders of the technology. This MOU' terms and conditions have been defined in view of a longer term partnership with a balanced distribution of tasks for each side.

The MOU signed with Technip, a major player in engineering, marks the inception of the roadmap for the L-methionine programme as presented in the publication of METabolic EXplorer's results on 23 March.

The roadmap concerns the implementation of partnerships based on four strategic and fully complementary strategic directions aimed at the industrial production of the new, 100% bio-based technology:

- Optimising the industrial investment for production unit sizes ranging from 10,00 to 80,000 tonnes a year through the initiation of reviews in collaboration with an internationally recognised engineering specialist
- Quantifying the nutritional, health and economic benefits of METEX L-methionine through the launch of animal testing in collaboration with leading animal nutrition companies and bodies. The first results are expected at the end of 2015
- Expanding regulatory filings to strategic geographical areas to bring future METEX licence holders global marketing access for L-methionine. The first filings will be made at the end of 2015
- Stepping up discussions underway with a view to signing non-exclusive licences. The first such signature is planned for late 2015.

-ENDS-

About METabolic EXplorer - www.metabolic-explorer.com

METabolic EXplorer is a biological chemistry company which was incorporated in 1999. Its goal is to help industrial businesses deal with the rise in oil prices, so that they can continue their production, in a different, sustainable way.

Based on the tried and tested principle of industrial fermentation, METabolic EXplorer's solutions replace today's petrochemical processes with the use of a wide range of plant-based raw materials. By optimizing the metabolic yield of non-pathogenic bacteria in a contained, controlled environment, the company facilitates the production of chemical compounds used in a wide range of everyday goods (textile fibres, paints, solvents, plastics and animal feed).

METabolic EXplorer is currently focusing its alternative processes on the production of three compounds that together have an estimated, annual, end-market value of €7 billion. The company's strategy will be implemented through industrial partnerships in the shape of joint ventures and licences, as well as own-account production units.

METabolic EXplorer, based in Clermont-Ferrand, France, is listed on NYSE Euronext in Paris (Compartment C, METEX) and is part of the CAC Small index.

*Get free financial information on METabolic EXplorer by registering with:
www.metabolic-explorer.com or www.actus-finance.com*

Media and individual shareholder relations

ATTITUDE Corporate

Eric de Lambert

E-mail : edelambert@attitude-corporate.com

Tél. : +33 (0)1 4970 4341 / +33 (0)6 2529 0658

Investor and analyst relations

ACTUS Finance et Communication

Jérôme Fabreguettes-Leib

E-mail: jfl@actus.fr

Tel: +33 (0)1 53 67 36 78

This communication includes forward-looking information which is subject to risks and uncertainties. The potential development of the company could be substantially different from that anticipated in this press release because of the various risk factors which are described in the company's Listing Prospectus.